Investigation launched into Curanex Pharmaceuticals over potential securities fraud after stock volatility.

Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into Curanex Pharmaceuticals and certain officers for possible securities fraud following extreme stock price volatility after its IPO in August 2025. The stock price surged from $4.00 at IPO to a peak of $9.16 before crashing to $1.51 amidst heavy trading volumes, leading to a trading halt. Shareholders who suffered losses may have claims, and the law firm is inviting affected investors to contact them for potential legal action. This investigation highlights risks in volatile biotech stocks and may lead to shareholder litigation if wrongdoing is found.